Meningococcal ACWY Conjugate Vaccine | Menveo - GSK

Advanced Meningococcal Disease Immunization

When protecting patients against the severe, rapid-onset, and potentially life-threatening impacts of invasive meningococcal disease (including meningitis and septicemia), healthcare providers require a comprehensive and highly reliable clinical intervention. The Meningococcal Group A, C, W135 and Y Conjugate Vaccine Ph. Eur. (commercially recognized as Menveo) provides targeted, active immunization strictly designed for intramuscular (IM) administration. Manufactured by GlaxoSmithKline (GSK), a global pioneer in advanced immunology, this specialized two-component clinical kit ensures the powerful clinical performance necessary for critical vaccination protocols.

Why Choose Menveo for Clinical Immunization?

Shielding patients from Neisseria meningitidis requires targeted serogroup coverage, as the bacteria can cause devastating illness within hours. Clinical specialists rely on Menveo because its advanced quadrivalent formulation protects against four major disease-causing serogroups (A, C, W135, and Y). By utilizing conjugate vaccine technology—binding the meningococcal oligosaccharides to a highly immunogenic CRM197 carrier protein—Menveo ensures a more robust and longer-lasting T-cell-dependent immune response compared to older polysaccharide alternatives.

Key Product Specifications & Clinical Benefits

Quadrivalent Broad Coverage: Delivers active protection against four major serogroups of meningococcal bacteria: A, C, W135, and Y.

Two-Component Clinical Kit: Each single dose consists of two critical vials that must be reconstituted together: 1 vial of Men A Lyophilized (freeze-dried) Conjugate Component and 1 vial of Men CWY Liquid Conjugate Component.

Precise Single Dose: Once reconstituted, the kit provides exactly one 0.5 mL dose for clinical administration.

Targeted Intramuscular Delivery: Formulated strictly for Intramuscular Injection, guaranteeing optimal absorption and systemic immune activation.

Essential Storage & Usage Guidelines

Maintaining the delicate biological integrity of this conjugate vaccine is absolutely vital for its clinical efficacy.

Strict Cold Chain: Store both vials strictly in a refrigerator between 2°C to 8°C.

Do Not Freeze: Freezing will irrevocably destroy the active vaccine structure. Discard immediately if either component has been frozen. Protect from light.

Preparation: The vaccine must be reconstituted by withdrawing the entire contents of the liquid Men CWY vial and injecting it into the lyophilized Men A vial. Shake well to ensure a clear to slightly opalescent solution before administration.

Important Notice: Menveo is a Prescription Drug. It must be prescribed, handled, prepared, and administered strictly by a Registered Medical Practitioner in a clinical or hospital setting. Keep all medicines safely out of the reach of children.